New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:43 EDTOMEDOncoMed recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the recent pullback in shares of OncoMed following the FDA's partial clinical hold on vantictumab as a buying opportunity. Piper wants to own shares ahead of the company's data read-outs in the second half of 2014. It reiterates an Overweight rating on the stock with a $43 price target.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
08:40 EDTOMEDOncoMed completes enrollment of tarextumab Phase 2 ALPINE clinical trial
Subscribe for More Information
August 20, 2015
05:48 EDTOMEDMizuho keeps TESARO, Verastem, OncoMed as top biotech picks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use